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Abstract 
Background: CDC25 phosphatases control cell cycle progression by activating cyclin 
dependent kinases. The three CDC25 isoforms encoding genes are submitted to 
alternative splicing events which generate at least two variants for CDC25A and five for 
both CDC25B and CDC25C. An over-expression of CDC25 was reported in several types 
of cancer, including breast cancer, and is often associated with a poor prognosis. 
Nevertheless, most of the previous studies did not address the expression of CDC25 
splice variants. Here, we evaluated CDC25 spliced transcripts expression in anti-
cancerous drug-sensitive and resistant breast cancer cell lines in order to identify 
potential breast cancer biomarkers. 
Methods: CDC25 splice variants mRNA levels were evaluated by semi-quantitative RT-
PCR and by an original real-time RT-PCR assay. 
Results: CDC25 spliced transcripts are differentially expres-sed in the breast cancer cell 
lines studied. An up-regulation of CDC25A2 variant and an increase of the CDC25C5/C1 
ratio are associated to the multidrug-resistance in VCREMS and DOXOR breast cancer 
cells, compared to their sensitive counterpart cell line MCF-7. Additionally, CDC25B2 
tran-script is exclusively over-expressed in VCREMS resistant cells and could therefore 
be involved in the development of certain type of drug resistance. 
Conclusions: CDC25 splice variants could represent interesting potential breast cancer 
prognostic biomarkers. 
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